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ABSTRACT
Purpose: We documented the results of high energy tran su re th ra l microwave therm otherapy in 
the  trea tm en t of benign pro static hyperplasia.
M aterials and Methods: We evaluated 116 patients following tran su re th ra l microwave th er­
m otherapy according to symptom scores, transrec ta l ultrasound, free voiding and pressure-flow 
study param eters.
Results: Significant im provement was noted in all objective and subjective param eters. More­
over, cavities in the prostatic u re th ra  were observed in almost 40% of the patients.
Conclusions: High energy transu re th ra l microwave therm otherapy is an effective therapy for 
benign prostatic hyperplasia. Patients w ith larger prostates and moderate to severe bladder 
outlet obstruction seem to be the best candidates for th is higher energy therm otherapy protocol, 
although morbidity is increased.
Key Words: prostatic hypertrophy; hyperthermia, induced; microwaves
Bladder outlet obstruction in men has been a clinical prob­
lem throughout medical history. As early as the 17th century 
it was suggested that benign prostatic hyperplasia (BPH) 
could result in mechanical obstruction of the bladder outlet, 
which may eventually cause lower urinary tract symptoms, 
inefficient bladder emptying with poor urinary flow and/or 
post-micturition residual urine.1 At this juncture the patient 
usually seeks medical advice either because of troublesome 
symptoms or complaints secondary to the worsened voiding, 
for example recurrent urinary tract infections.
Presently, transurethral resection of the prostate is the 
gold standard therapy for BPH, affording excellent results in 
the hands of the experienced surgeon. The success of trans­
urethral resection of the prostate is defined by the immediate 
removal of obstructing prostatic tissue resulting in the for­
mation of cavities. Long lasting improvement in symptoms 
and voiding parameters is achieved within a few days of 
treatment. However, this operation is not to be taken lightly.
Although the mortality rate has decreased to 0.5%,2 the 
morbidity rate after transurethral resection of the prostate is 
still 18% and has not altered significantly within the last 15 
years. Consequently, despite the proved safety and efficacy of 
this procedure, its morbidity as well as its relatively high cost 
and invasive nature have led many investigators to search 
for an alternative treatment.
Many techniques that minimize the physiological effects 
associated with prostatic surgery are currently being as­
sessed, including use of prostatic stents,3 transurethral 
needle ablation,^ high intensity focused ultrasound,5 trans­
urethral microwave thermotherapy6 and laser therapy.7 The 
question as to which technique is appropriate in any individ­
ual is answered largely by knowing the outcome of each of 
these therapies. Despite the encouraging results claimed for 
all of the new techniques, transurethral resection of the
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prostate continues to surpass its competitors. However, the 
results of high energy thermotherapy seem to shed a new 
light on this discussion.
The results reported with lower energy thermotherapy us­
ing Prostasoft 2.0* in the treatment of BPH are promising. 
Overall symptomatic improvement has been reported in the 
majority of patients in conjunction with improvement of void­
ing parameters.8-10 The Madsen symptom score decreased 
from a mean of 13 before treatment to about 4 after treat­
ment, while mean maximum flow change ranged from 2 to 3 
ml. per second. It has been suggested that the placebo re­
sponse with this modality may contribute considerably to 
treatment outcome. However, 5 sham controlled studies have 
demonstrated that the effect of transurethral microwave 
thermo therapy is greater than can be accounted for by either 
the associated urethral instrumentation or by any placebo 
effect.11 The re-treatment rate after transurethral micro­
wave thermotherapy was reportedly 0.5 to 11% at 1 year of 
followup.9-10-12
An increase in thermal dose can be seen with the evolution 
of thermal treatment modalities. The elevation of intrapros­
tatic temperatures as measured by invasive thermometry 
during transurethral microwave thermotherapy using ver­
sion 2.0 operating software has been shown to be broadly 
correlated with clinical outcome.13 Program version 2.0 was 
modified to provide more power at a maximum of 70 watts, 
and uses a higher rectal threshold leading to an increase in 
the energy delivered to the prostate. This new version of the 
operating software, known as Prostasoft version 2.5, is cur­
rently under evaluation. In contrast to earlier reports on 
results achieved with lower energy thermotherapy, the re­
sults with these higher energy levels seem to be excellent, 
and in a subgroup of patients they are even comparable to 
those of surgical therapy. We present the results of a multi­
center study using high energy thermo therapy for the treat­
ment of BPH.
* Technomed Medical Systems, Lyon, France.
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P A T IE N T S  AND M E T H O D S
Patients recruited for the study had a Madsen symptom  
score of 8 or more, maxi mum flow rate 15 ml. per second or 
less, post-void residual 350 ml. or less and voided volume 100 
ml. or more. Assessm ent of these patients included history 
with symptom scores, physical examination with digital rec­
tal examination, biochemistry investigations including pros­
tate specific antigen, urinalysis, urine culture, transrectal 
ultrasonography of the prostate, uroflowmetry, post-void re­
sidual measurement and a urodynamic investigation includ­
ing pressure-flow studies. The results of high energy thermo­
therapy in 116 men with lower urinary tract symptoms and 
BPH were evaluated, and outcome was correlated with pros­
tate size, International Prostatic Symptom Score (I-PSS), 
Madsen symptom score, free flow voiding parameters and 
grade of bladder outlet obstruction. Followup was performed 
at 4, 12, 26 and 52 weeks after treatment.
We used the Prostatron:!: device with a COO treatment 
catheter consisting of a microwave dipole antenna positioned 
10 mm. below the Foley balloon and mounted in a water 
cooled transurethral probe. Version 2.5 of the high energy 
operating software provides power at a maximum of 70 watts 
with a rectal threshold set at 43.5C. Transurethral micro­
wave thermotherapy has been described previously.14
Uroflowmetry was performed, and the post-void residuals 
were determined by transabdominal ultrasound using the 
ellipsoid formula. Urodynamic investigations were per­
formed with a transurethral catheter equipped with an in­
travesical microtip pressure sensor for bladder pressure re­
cordings. The abdominal pressure was recorded intrarectally 
with a microtip sensor catheter. Commercially available 
equipment was used to record the pressure and flow data. 
The digitally stored data were translated to a urodynamics 
analysis computer program developed at our department. To 
provide objective and precise grades of obstruction, pressure- 
flow study graphs were fitted to a passive urethral resistance 
relation curve. The minimal urethral opening pressure and 
theoretical urethral lumen were calculated automatically.15 
The urethral resistance factor was computed to enable the 
classification of patients on a continuous, 1 parameter scale 
of obstruction.16 We also added a non parametric analysis of 
obstruction using a classification according to the linear pas­
sive urethral resistance relation pressure-flow study nomo­
gram.17
R E S U L T S
Between April 1993 and July 1994, 116 patients were 
treated with high energy transurethral microwave thermo­
therapy using the Prostasoft 2.5 software. Patient age at 
baseline ranged from 50 to 87 years (mean 66.6) and average 
prostate volume plus or minus standard deviation was 51 ± 
21 cm.3 (range 20 to 154). Madsen symptom scores ranged 
from 8 to 23 (mean 13.6 ±  3,6). Uroflowmetry parameters 
showed a maximum flow rate of 3 to 15 ml. per second (mean 
9.6 ± 3.3), voided volume 100 to 697 ml. (mean 227 ±  127)
and post-void residual 0 to 350 ml. (mean 73 ± 79). An 
average of 147 ± 44 kJ. (range 28 to 209) of microwave 
energy were administered during treatment.
Of the patients 67 have reached 1 year of followup, while 
105 were followed 26 weeks. Among the 11 patients who were 
not seen at 26 weeks 2 died of nontreatment related causes (1 
of terminal heart failure 4 months after treatm ent and 1 of 
pulmonary failure due to a 1-antitrypsin deficiency), 3 under­
went transurethral resection of the prostate and 6 were lost 
to followup. Mean Madsen symptom score at baseline was 
13.6, and improved to 9.4 at 4 weeks, 6.0 at 12 weeks, 5.5 at 
26 weeks and 4,9 at 52 weeks of followup (fig. 1, A). The I-PSS 
showed a similar pattern, with improvement from a m ean of 
17.5 at baseline to 13.9 at 4 weeks, 8.2 at 12 weeks, 7.9 at 26 
weeks and 7.1 at 52 weeks of followup (fig. 1, B). Maximum  
flow rate improved from 9.6 ml. per second at baseline to 9.8 
at 4 weeks, 15.2 at 12 weeks and 14.1 at 26 weeks of followup. 
These improvements were sustained to 52 weeks, with a 
maximum flow rate of 14.5 ml. per second (fig. 1, C). The 
voided volume during followup increased slightly (fig. 2, A), 
while the post-void residual decreased significantly from 73 
ml. at baseline to 40 ml. at 4 weeks, 27 at 12 weeks, 33 at 26 
weeks and 25 at 52 weeks of followup (fig. 2, B). Mean 
duration of transurethral drainage was 14.3 ±  15.2 days 
(range 0 to 105).
Transrectal ultrasonography at 3 months of followup iden­
tified a cavity in 37% of the patients (fig. 3). There appeared 
to be good statistical correlation between the presence of 
cavities and uroflowmetry improvement (p = 0.003). M axi­
mum flow rate improved from 9.7 ml. per second at baseline 
to 17.9 ml. per second in  patients with a cavity on transrectal 
ultrasound and from 9.6 to 13.6 ml. per second in those 
without a cavity. Currently, data for 83 patients are available 
for urodynamic analysis. At 6 months after transurethral 
microwave thermotherapy a statistically significant improve­
ment was noted for all pressure-flow parameters, which is 
also clearly illustrated in the Abrams-Griffith nomogram (fig. 
4 and table 1). Baseline parameter stratification versus 
treatm ent outcome showed that particularly patients with  
larger prostates and moderate to severe bladder outlet ob­
struction respond best to high energy transurethral micro­
wave thermotherapy (table 2). These patients showed a sig­
nificant improvement in objective and subjective parameters. 
The relationship between maximum flow rate at baseline and 
treatment outcome was much less. There appeared to be no 
relationship between treatm ent outcome and M adsen symp­
tom score at baseline.
High energy thermotherapy resulted in considerable mor­
bidity. Irritative voiding complaints were noted in a large 
number of patients for up to 2 to 4 weeks, and transient 
hematuria was present in most patients during the first days 
after treatment. Finally, retrograde ejaculation was docu­
mented in a third of the patients who had antegrade ejacu­
lation before treatment.
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Fig . 1. Changes in clinical parameters after treatment with means and standard errors. A, Madsen symptom score. £ , I-PSS. C , maximum 
free flow, N, number of patients.
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T a b l e  1. Urodynamic data at baseline and after treatment
Mean
Before
Treatment
± SD
After
Treatment
Pressure at maximum flow 64 ± 2 3 39 ± 16
Linear passive urethral 2,9 ± 1.3 1.3 ± 1.1
resistance relation
Urethral resistance factor 41 ± 15 23 ± 11
Minimal urethral opening 33 ± 17 16 ± 9
pressure
Theoretical urethral lumen 2.8 ±  1.3 6.2 ± 5.1
pulmonary diseases and high operative risks, a minimally 
invasive treatment has been sought, including medica­
tion20»21 and instrumentation.3“7 With the concept of trans­
urethral microwave thermotherapy as an outpatient and 
anesthesia-free procedure, and the encouraging clinical re­
sults achieved to date, much effort has been concentrated on 
developing this treatment modality.
Application of higher energy levels for thermotherapy us­
ing Prostasoft 2.5 software was first reported by Devonec6 
and de la Rosette11 et al, who demonstrated clinically signif­
icant improvement. Our present multicenter study confirms 
these results. The changes in subjective parameters using 
the high energy Prostasoft 2.5 software is similar to the 
improvement noted in patients treated with the Prostasoft 
2.0 version.6 However, when comparing the objective param­
eters, a significantly better outcome in terms of urinary peak 
flow change was noted. A statistically significant increase in 
maximum flow of 9.6 to 15.2 ml. per second was noted at 12 
weeks after transurethral microwave thermotherapy, which 
was sustained to at least 1 year. Mean post-void residual also 
improved significantly from 73 to 27 ml. at 12 weeks and 25 
ml. at 1 year. This objective improvement in uroflowmetry 
results was much more pronounced than in patients treated 
with the lower energy software. Transrectal ultrasound im­
aging of the prostate identified a cavity in 37% of the patients 
at 3 months after treatment (fig. 3). A positive correlation 
between the presence of such a cavity and urinary flow rate 
improvement was observed. One may conclude that more 
energy delivered to the prostate seems to result in greater 
improvement in objective parameters, which may be ex­
plained by the creation of cavities within the prostate. How­
ever, when such a cavity is absent the treatment should not 
be regarded as a failure because uroflowmetry may improve 
independent of cavitjf formation.
Although uroflowmetry is an excellent method to document 
the act of micturition, and it may indicate whether an abnor­
mality is present, its role in defining the grade of obstruction 
is limited.22 For transurethral microwave thermotherapy to 
be regarded as proper therapy for BPH, it must be able to 
relieve the outlet obstruction. Advanced urodynamics, in­
cluding pres sure-flow study analysis, are considered the best
methods to document changes in the grade of obstruction.22 
The changes in pressure-flow study parameters were only 
moderate with the lower energy Prostasoft 2.0 software. We 
concluded that only a certain type of obstruction responded 
favorably to thermotherapy.23’24 In general, however, severe 
obstruction is not cured following low energy thermo therapy. 
Analysis of the urodynamic data at 6 months after transure­
thral microwave thermotherapy using Prostasoft 2.5 showed 
that 80% of obstruction patients appeared to be cured (fig, 4). 
A significant decrease in all obstruction parameters was 
noted overall (table 1), One can conclude that transurethral 
microwave thermotherapy using Prostasoft version 2.5 is 
able to relieve bladder outlet obstruction.
From an earlier study we learned that no single clinical 
parameter could predict which patients would respond best 
to low energy thermotherapy.25 Using high energy thermo­
therapy it appears that patients with more severe outlet 
obstruction and larger prostates will respond best. Further 
studies are required to explain this phenomenon. A possible 
explanation for the favorable outcome of treatment of larger 
prostates is a difference in tissue composition and tissue 
perfusion. It is well known that stromal tissue responds 
differently to heat than glandular tissue.26 Larger prostates 
may have a different distribution of stromal and glandular 
tissue, and consequently they may respond differently to 
thermotherapy. We also know that the temperature increase 
in the prostate depends strongly on the tissue perfusion, and 
that perfusion is known to increase with temperature during 
thermotherapy.27>28 One can speculate that in larger pros­
tates the tissue perfusion is less efficient than in smaller 
prostates, and that perhaps as a consequence higher temper­
atures can be achieved resulting in necrosis with formation of 
a cavity. Current thermotherapy systems do not consider the 
effect of tissue perfusion on the efficacy of the treatment.
Although urine flow is improved, the morbidity caused by 
high energy transurethral microwave thermotherapy is in­
creased compared to lower energy protocols. The high energy 
treatment is well tolerated by the patients but pain medica­
tion must be administered before or during therapy in most 
cases. On a trial and error basis, 30 mg. morphine sulfate 
administered 2 hours before therapy resulted in an almost 
complaint-free treatment. If requested, patients also were 
given either 10 mg. diazepam and/or 0,10 mg, fentanyl dur­
ing treatment. Perception of discomfort during transurethral 
microwave thermotherapy may vary from a mild sensation of 
perineal warmth and a mild urge to urinate to significant 
discomfort. However, the morbidity is clearly lower with 
transurethral microwave thermotherapy than with transure­
thral resection of the prostate. Transurethral microwave 
thermotherapy can still be performed as an outpatient pro­
cedure without general anesthesia, and it is particularly well 
suited for patients in poor health. Occasionally, hematuria 
and tissue slough are noted, and urinary retention is ex­
Ta b l e  2. Outcome of subjective (Madsen symptom score) and objective (maximum flow and pressure at maximum flow) parameters
according to results of maximum flow at baseline, prostate volume and grade of obstruction
- No.
Pts.
Mean Madsen Symptom 
Score ±  SD
Mean Maximum Free Flow
±  SD
Mean Detrusor 
Pressure at Maximum
Flow ±  SD
Baseline 12 Wks. Baseline 12 Wks. Baseline 26 Wks.
Maximum free flow (ml./sec.):
12 or More 36 13.8 ±  3.7 5.0 ±  4.9 13.5 ±  1.2 18.3 ± 5.9 67 ± 2 1 37 ±  17
Less than 12 80 13.5 ±  3.6 6.5 ± 4.4 7.9 ±  2.2 14.0 ± 6.4 62 ± 2 4 39 ±  15
Prostatic vol. (cc):
40 or More 77 13.4 ±  3.6 5.8 + 4.3 9.8 ±  3.4 16.5 ± 7.1 6 8  ± 2 1 38 ± 16
Less than 40 39 13.8 ±  3.7 6.4 ±  5.0 9.3 ±  3.0 13.2 ±  4.6 53 ± 2 4 41 ± 15
Linear passive urethral resistance 
relation:
3 or More 52 13.7 ±  3.5 5.7 ±  4.4 9.5 ± 3.4 16.9 ±  7.1 78 ± 15 42 ±  17
Less than 3 31 14.2 ± 3.9 8.0 ±  4.6 9.1 ±  3.1 14.0 ± 6.5 40 ± 1 0 33 ±  13
HIGH ENERGY THERMOTHERAPY FOR BENIGN PROSTATIC HYPERPLASIA 101
pected in almost all patients. Catheterization interval aver­
aged 14.3 days (range 0 to 105) and patients with larger 
prostates required longer catheterization periods than those 
with smaller prostates. The finding of retrograde ejaculation 
in a third of our patients is in contrast to those documented 
with lower energy thermotherapy, in which antegrade ejac­
ulation was unchanged in the majority of patients.29
No bladder neck contraction or urethral strictures have 
been noted to date. Treatment was repeated in 3 patients 
because they were not satisfied with the result. From the 
long-term foliowup data using Prostasoft 2.0 we have learned 
that the re-treatment rate at 1 year is estimated up to 10%,30 
while 3-year followup data by de Wildt and de la Rosette,27 
and Dahlstrand et al31 indicate that clinical benefit is sus­
tained for this period. One may expect that the results 
achieved with the higher energy software are at least as 
good.
In conclusion, high energy transurethral microwave ther­
motherapy shows significant subjective and objective im­
provement. The best candidates are patients with moderate 
to severe bladder outlet obstruction and larger prostates. 
Formation of cavities after treatment correlated well with 
better clinical outcome.
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EDITORIAL COMMENT
The authors introduce the results of a multicenter trial of high 
energy transurethral microwave thermo therapy. In this regard the 
lower energy Prostasoft 2.0 software was altered. The power was 
increased to a maximum of 70 watts compared to 60 watts, and rectal 
temperature safety thresholds were increased from 42.5 to 43.5C. Of
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116 patients treated 67 were followed for 1 year. The overall magni­
tude of response in terms of symptom scoring, peak flow rate and 
post-void residual seems to be superior to that obtained with the 
prior software (references 6, 8 to 10, 12 and 13 in article).
The authors attribute the improved results to a higher energy 
delivered to the prostate, resulting in a wider zone of tissue 
destruction and subvesical cavities in 37% of the patients. Thus, 
improvement in mean peak flow rate changes at 12 months ap­
proached 5 cc per second with a statistically significant decrease 
in post-void residual and an increase in voided volume. However, 
symptomatic improvement does not appear to be significantly 
different than what can be achieved in symptom score with the 
Prostasoft 2.0 software. The downside to using this software, 
however, has been an increase in the morbidity of the procedure 
and prolonged retention rate. These morbidities remain substan­
tially less than those of transurethral resection, since patients are 
treated on an outpatient basis without requiring general anesthe­
sia, although liberal parenteral sedation and analgesia were nec­
essary. Considerable irritative voiding complaints that persisted
for up to 4 weeks after the procedure are reminiscent of the 
experience with laser prostatectomy.
It is clear that transurethral microwave thermotherapy is devel­
oping its role as an alternative in the management of BPH. The 
investigators continue to provide these data. A randomized prospec­
tive study with this large population of patients comparing Prosta­
soft versions 2.0 and 2.5 more clearly have placed the high energy 
treatment in its proper perspective. While it is apparent that symp­
tomatic improvement is substantially the same for both versions, is 
it necessary to increase morbidity to improve urodynamic parame­
ters? Does the creation of a subvesical cavity result in a more durable 
treatment? These questions will be answered as transurethral mi­
crowave thermo therapy continues to increase its role in the overall 
management of this disease.
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